Regeneron Pharmaceuticals, Inc. (REGN)
951.19
-8.22
(-0.86%)
USD |
NASDAQ |
Nov 12, 16:00
953.91
+2.72
(+0.29%)
After-Hours: 20:00
Regeneron Pharmaceuticals EPS Diluted (Quarterly) : 18.45 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 18.45 |
| June 30, 2026 | 12.23 |
| March 31, 2026 | 6.752 |
| December 31, 2025 | 7.857 |
| September 30, 2025 | 13.62 |
| June 30, 2025 | 12.81 |
| March 31, 2025 | 7.272 |
| December 31, 2024 | 8.064 |
| September 30, 2024 | 11.54 |
| June 30, 2024 | 12.41 |
| March 31, 2024 | 6.273 |
| December 31, 2023 | 10.19 |
| September 30, 2023 | 8.887 |
| June 30, 2023 | 8.502 |
| March 31, 2023 | 7.174 |
| December 31, 2022 | 10.50 |
| September 30, 2022 | 11.66 |
| June 30, 2022 | 7.475 |
| March 31, 2022 | 8.607 |
| December 31, 2021 | 19.69 |
| September 30, 2021 | 14.33 |
| June 30, 2021 | 27.97 |
| March 31, 2021 | 10.09 |
| December 31, 2020 | 10.24 |
| September 30, 2020 | 7.393 |
| Date | Value |
|---|---|
| June 30, 2020 | 7.611 |
| March 31, 2020 | 5.43 |
| December 31, 2019 | 6.929 |
| September 30, 2019 | 5.863 |
| June 30, 2019 | 1.685 |
| March 31, 2019 | 3.99 |
| December 31, 2018 | 7.15 |
| September 30, 2018 | 5.17 |
| June 30, 2018 | 4.82 |
| March 31, 2018 | 4.16 |
| December 31, 2017 | 1.50 |
| September 30, 2017 | 3.32 |
| June 30, 2017 | 3.34 |
| March 31, 2017 | 2.16 |
| December 31, 2016 | 2.19 |
| September 30, 2016 | 2.27 |
| June 30, 2016 | 1.69 |
| March 31, 2016 | 1.59 |
| December 31, 2015 | 1.34 |
| September 30, 2015 | 1.82 |
| June 30, 2015 | 1.69 |
| March 31, 2015 | 0.66 |
| December 31, 2014 | 0.96 |
| September 30, 2014 | 0.70 |
| June 30, 2014 | 0.82 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.942 |
| AbbVie, Inc. | 2.373 |
| Vertex Pharmaceuticals, Inc. | 2.561 |
| Amgen, Inc. | 7.077 |
| Biogen, Inc. | -0.1394 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.949B |
| Revenue (Quarterly) | 5.116B |
| Total Expenses (Quarterly) | 3.167B |
| Enterprise Value | 91.75B |
| Gross Profit Margin (Quarterly) | 86.42% |
| Profit Margin (Quarterly) | 38.09% |
| Earnings Yield | 4.76% |
| Operating Earnings Yield | 5.06% |
| Normalized Earnings Yield | 5.134 |